Aoxing Pharmaceutical Company, Inc. · OTC:AOXG
Aoxing Pharmaceutical — China Aoxing Pharmaceutical Company — Adam Friedman conference (November 2007)
17 slides from Aoxing Pharmaceutical's conference presentation, Nov 7, 2007
Slide 1: China Aoxing Pharmaceutical Co., Inc. Investor Presentation
China Aoxing Pharmaceutical Co.,Inc. Investor Presentation Specialty Pharma Focused on Narcotics and Pain Medicines in China OTC BB: CAXG November 2007
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements including statements regarding the timing and outcome of product development, potential regulatory approvals, future demand for and sales of our products and future development of new products. These statements are not guara
Slide 3: CAXG Investment Highlights
CAXG Investment Highlights * Strong pipeline of narcotics and pain medicines - Two drugs currently approved (Naloxone HCI & Shuanghuanglian) - Seven drugs set for approval in 2007, 2008 & 102009 + Growing and underserved market for narcotics and pain medicine in China - Currently US§ 2 billion annua
Slide 4: CAXG Strong Pain Medicine Product Portfolio
CAXG Strong Pain Medicine Product Portfolio* DevelopmentStatus Drug Indication Peer Product Launch Study Review Naloxone HCl injactable Pid leohol Shuanghuangtan ry cold Fu Pholeodine Coush Sup AS 4007-1008 Paracetomal & Caffeine Parco i —~— 4007-1008 ‘Oxycodone dna CTablts ad Capsuls) —— — 208 Tild
Slide 5: Current Products Being Sold
Current Products Being Sold Naloxone HCI Injectable + Launched product February 2007 + One of the three API domestic producers + Highly controlled substance + Treatment for narcotic addiction & alcoholism + Used post-anesthesia + CAXG sales potential estimated at $30MM Shuang Cough and Cold Capsules
Slide 6: Compelling Product Pipeline: 2007 & 2008
Compelling Product Pipeline: 2007 & 2008” Oxycodone + Top selling narcotic drug globally, No product currently manufactured by domestic drug maker + Product launch expected in 208-109 Tilidine + Leading cancer pain medicine in Europe, estimated 300MM Euro annually, not yet available in China + CAXGi
Slide 7: Research & Development
Research & Development Expertise + API chemical synthesis, proprietary formulation development, PK/PD studies, drug safety and toxicology + Specialized team in documentation, drug application and SFDA regulatory filing + 50 members with extensive R&D experience Partnerships + Labtech Pharma AG — To
Slide 8: SFDA Narcotic Drug Oligopoly Allocation & Approval Process
SFDA Narcotic Drug Oligopoly Allocation & Approval Process SFDA selects specific narcotics, amounts, and allocates to 2.3 qualified producers => CAXG gets pre-approval R&D license from SFDA 1 month =) CAXG develops API, formulates, conducts pilot production, animal testing — 3-412 months CAXG conduc
Slide 9: Market Drivers of Narcotics & Pain Medicines in China
Market Drivers of Narcotics & Pain Medicines in China 1 Prior to 2000, very few narcotics In China, ~ 1% of the US market, currently $300MM, 30% CAGR 2 New government efforts to Increase supply, especially from domestic producers feetieraentard effective treatments, especially for cancer, most letha
Slide 10: Sales & Marketing Strategy
Sales & Marketing Strategy Sales Force + 120 highly experienced and well-trained professionals + LRT acquisition will increase the sales force to over 500 by 1H'08 + Coverage of major cities and 27 of 30 provinces + 3 large regional and 100 branch offices , and 1000+ independent distributors Product
Slide 11: State-of-The-Art Facility - Hebei Province, China
State-of-The-Art Facility - Hebei Province, China Current size of facility: 1.2 million square feet Completed size of facility :3.5 million square feet © China Aoxing i Pharmaceutical Co. Inc.
Slide 12: Current Manufacturing Capacity
Current Manufacturing Capacity Production Equipment State-of-the-art Bosch capsule filling machines; Ullmann fully automated packaging machines, etc. Forms. Current Capacity Tablet 160 Million Capsule 140 Million Injectable Solution 100 Million Oral Liquid 100 Million Granulated 100 Million Total An
Slide 13: Le Ren Tang (LRT) Acquisition Plan
Le Ren Tang (LRT) Acquisition Plan Comprehensive product line focusing on pain medication 127 SFDA approved products Currently only ~ 50 products in production Well-known brand, 70 year history Limited geographic marketing coverage Financial Summary + Immediately accretive + ¥2007 - $10MM sales and
Slide 14: Management with Over 90 Years Pharma Experience
Management with Over 90 Years Pharma Experience Board of Directors — Strong and experienced, consists of CEO, SVP and 3 outsiders Zhenjiang Yue + 25 years of entrepreneurial experience Chairman & CEO + Founded four companies, last 11 years in heattheare industry Zhanyi Liu ‘¢ 25 years senior managem
Slide 15: Timeline of Events 2007 & 2008
Timeline of Events 2007 & 2008 4007 1H08 2H08 Complete LRT Acquisition, the Company becomes immediately profitable Inctease the sales force from 120 to 500 upon LAT integration Expect SFDA approval for Pholcodine for cough® Complete clinical trial of Tilidine for moderate to severe pain (400 subject
Slide 16: CAXG Investment Highlights
CAXG Investment Highlights * Strong pipeline of narcotics and pain medicines - Two drugs currently approved (Naloxone HCI & Shuanghuanglian) - Seven drugs set for approval in 2007, 2008 & 102009 + Growing and underserved market for narcotics and pain medicine in China - Currently US§ 2 billion annua
Slide 17: Thank you for your time and attention!
Thank you for your time and attention! BA) China Aoxing y Pharmaceutical Co.,Inc.
China Aoxing Pharmaceutical Company — Adam Friedman conference (November 2007) on 6ix